ArticlePloS one2013
The proton-pump inhibitor lansoprazole enhances amyloid beta production.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 4 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Proton Pump Inhibitor Use and Risk of Dementia: An Umbrella Review of Systematic Reviews and Meta-Analyses.Digestive diseases and sciences · 2026Pooled it
- A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer's disease and gastrointestinal tract disorders.Communications biology · 2022Pooled it
- Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies.European journal of clinical pharmacology · 2020Pooled it
- Pooled it
- Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.PloS one · 2017Trial
- Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.Alzheimer's research & therapy · 2015Trial
- Sustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study.BMJ open ophthalmology · 2026Observational
- Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study.Journal of Korean medical science · 2026Article
- Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study.European archives of psychiatry and clinical neuroscience · 2025Article
- Long-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole.Annals of medicine and surgery (2012) · 2025Review
- Association Between Polypharmacy and Self-Reported Hearing Disability: An Observational Study Using ATC Classification and HHIE-S-It Questionnaire.Audiology research · 2025Article
- Regenerative Medicine in the Treatment of Alzheimer's Disease: A Narrative Review.Iranian journal of public health · 2025Review
- Co-Deposited Proteins in Alzheimer's Disease as a Potential Treasure Trove for Drug Repurposing.Molecules (Basel, Switzerland) · 2025Article
- Protective mechanism of apigenin in proton pump inhibitor-associated progressive cognitive impairment in adult zebrafish via targeting GSK-3β pathway.Metabolic brain disease · 2025Article
- Exploring Potential Medications for Alzheimer's Disease with Psychosis by Integrating Drug Target Information into Deep Learning Models: A Data-Driven Approach.International journal of molecular sciences · 2025Article
- The impact of proton pump inhibitors on brain health based on cross-sectional findings from the Rhineland Study.Scientific reports · 2024Article
- Association between proton pump inhibitors and dementia risk: a Mendelian randomization study.Scientific reports · 2024Article
- Potential Risks Associated With Long-term Use of Proton Pump Inhibitors and the Maintenance Treatment Modality for Patients With Mild Gastroesophageal Reflux Disease.Journal of neurogastroenterology and motility · 2024Review
- Proton pump inhibitors and dementia: A nationwide population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks.Current Alzheimer research · 2024Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Based on a systems biology study to repurpose drugs for AD, we explore the effect of lansoprazole, and other proton-pump inhibitors (PPIs), on Aβ production in AD cellular and animal models. We found that lansoprazole enhances Aβ37, Aβ40 and Aβ42 production and lowers Aβ38 levels on amyloid cell models. Interestingly, acute lansoprazole treatment in wild type and AD transgenic mice promoted higher Aβ40 levels in brain, indicating that lansoprazole may also exacerbate Aβ production in vivo. Overall, our data presents for the first time that PPIs can affect amyloid metabolism, both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.